{
    "clinical_study": {
        "@rank": "104355", 
        "arm_group": [
            {
                "arm_group_label": "onabotulinumtoxinA Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose 1 injected into protocol-specified areas on Day 1."
            }, 
            {
                "arm_group_label": "onabotulinumtoxinA Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose 2 injected into protocol-specified areas on Day 1."
            }, 
            {
                "arm_group_label": "Placebo (normal saline)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (normal saline) injected into protocol-specified areas on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX\u00ae) compared\n      with placebo as treatment for major depressive disorder (MDD) in adult females."
        }, 
        "brief_title": "OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Depressive Disorder, Major", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Moderate to severe major depressive disorder\n\n        Exclusion Criteria:\n\n          -  Prior treatment with botulinum toxin of any serotype for any reason\n\n          -  Use of antidepressant medication for depression within 2 weeks of study\n\n          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116361", 
            "org_study_id": "191622-135"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "onabotulinumtoxinA Dose 1", 
                    "onabotulinumtoxinA Dose 2"
                ], 
                "description": "OnabotulinumtoxinA injected into protocol-specified areas on Day 1.", 
                "intervention_name": "onabotulinumtoxinA", 
                "intervention_type": "Biological", 
                "other_name": [
                    "BOTOX\u00ae", 
                    "botulinum toxin Type A"
                ]
            }, 
            {
                "arm_group_label": "Placebo (normal saline)", 
                "description": "Placebo (normal saline) injected into protocol-specified areas on Day 1.", 
                "intervention_name": "Normal Saline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 15, 2014", 
        "link": {
            "description": "More information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change From Baseline in the Clinic 10-Item Montgomery-Asberg Depression Rating Scale (MADRS) Total Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116361"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change From Baseline in the 7-Item Clinical Global Impression of Severity of Illness (CGI-S) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 24 Weeks"
            }, 
            {
                "measure": "Change From Baseline in the Clinic Hamilton Depression Rating Scale 17-Item Version (HAM-D\u02c717)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 24 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}